BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02684370 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

560

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: risankizumab
DRUG: placebo for risankizumab
DRUG: ustekinumab
DRUG: placebo for ustekinumab

Sponsor

AbbVie

Collaborators

[object Object]